newsfilter
← Latest News
Business Wire·

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage